74 related articles for article (PubMed ID: 27734130)
1. Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.
Koren-Michowitz M; Lavi N; Ellis MH; Vannucchi AM; Mesa R; Harrison CN
Ann Hematol; 2017 Jan; 96(1):87-92. PubMed ID: 27734130
[TBL] [Abstract][Full Text] [Related]
2. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.
Andreescu M; Andreescu B
Cureus; 2024 Mar; 16(3):e56008. PubMed ID: 38606222
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
Kucine N
Curr Hematol Malig Rep; 2020 Apr; 15(2):141-148. PubMed ID: 32172359
[TBL] [Abstract][Full Text] [Related]
4. A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis.
Kumar K; Koubeissy A; Pulenthiran A; Kumar A; Gulati A; Wolf B; Peeke S
Cureus; 2023 Dec; 15(12):e50679. PubMed ID: 38229794
[TBL] [Abstract][Full Text] [Related]
5. Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.
Krecak I; Verstovsek S; Lucijanic M
Clin Adv Hematol Oncol; 2023 Oct; 21(10):541-548. PubMed ID: 37948590
[TBL] [Abstract][Full Text] [Related]
6. How I treat myeloproliferative neoplasms in pregnancy.
Robinson S; Ragheb M; Harrison C
Blood; 2024 Feb; 143(9):777-785. PubMed ID: 38145575
[TBL] [Abstract][Full Text] [Related]
7. UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN.
Harrison C; Mathias J; Campbell-Drew M; Mead AJ; Pemberton-Whiteley Z; Ali S; Wadelin F; Taylor-Stokes G; Waller J; Taylor B
Br J Haematol; 2019 Aug; 186(3):e1-e4. PubMed ID: 30854625
[No Abstract] [Full Text] [Related]
8. TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model.
Wang Z; Mei Y; Yang Z; Gao Q; Xu H; Han Z; Hong Z
Front Oncol; 2024; 14():1369346. PubMed ID: 38585007
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction.
Krecak I; Lucijanic M
JACC CardioOncol; 2023 Dec; 5(6):842. PubMed ID: 38205014
[No Abstract] [Full Text] [Related]
10. Reply: Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction.
Leiva O; Hobbs G; Bangalore S
JACC CardioOncol; 2023 Dec; 5(6):843-844. PubMed ID: 38205013
[No Abstract] [Full Text] [Related]
11. The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.
Gianelli U; Cattaneo D; Bossi A; Cortinovis I; Boiocchi L; Liu YC; Augello C; Bonometti A; Fiori S; Orofino N; Guidotti F; Orazi A; Iurlo A
Mod Pathol; 2017 Feb; 30(2):169-179. PubMed ID: 27739437
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
13. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.
Barbui T; Vannucchi AM; Carobbio A; Rumi E; Finazzi G; Gisslinger H; Ruggeri M; Randi ML; Cazzola M; Rambaldi A; Gisslinger B; Pieri L; Thiele J; Pardanani A; Tefferi A
Am J Hematol; 2017 Jan; 92(1):E5-E6. PubMed ID: 27737508
[No Abstract] [Full Text] [Related]
14. Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs.
Iurlo A; Bucelli C; Cattaneo D
Curr Treat Options Oncol; 2023 Jul; 24(7):802-820. PubMed ID: 37195587
[TBL] [Abstract][Full Text] [Related]
15. Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm.
Song IC; Kang S; Lee MW; Ryu H; Lee HJ; Yun HJ; Jo DY
Blood Res; 2023 Mar; 58(1):42-50. PubMed ID: 36774948
[TBL] [Abstract][Full Text] [Related]
16. 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events.
Gangat N; Szuber N; Jadoon Y; Farrukh F; Begna K; Elliott MA; Wolanskyj-Spinner AP; Hanson CA; Pardanani AD; De Stefano V; Barbui T; Vannucchi AM; Tefferi A
Blood Adv; 2022 Jul; 6(13):3835-3839. PubMed ID: 35271689
[No Abstract] [Full Text] [Related]
17. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
Stein BL; Martin K
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):397-406. PubMed ID: 31808903
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy.
Michowitz Y; Klempfner R; Shlomo N; Goldenberg I; Koren-Michowitz M
PLoS One; 2019; 14(11):e0224709. PubMed ID: 31697741
[TBL] [Abstract][Full Text] [Related]
19. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.
Harrison CN; McLornan DP
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):489-497. PubMed ID: 29222297
[TBL] [Abstract][Full Text] [Related]
20. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.
Boddu P; Falchi L; Hosing C; Newberry K; Bose P; Verstovsek S
Leuk Res; 2017 Jul; 58():14-22. PubMed ID: 28380402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
